Overview
Cardiovascular toxicity of carfilzomib, a last generation proteasome inhibitor, is highly incident according to retrospective data. Prospective cohort study of patients initiated on carfilzomib.
Eligibility
Inclusion Criteria:
- Intention to treat by Carfilzomib
Exclusion Criteria:
- History of carfilzomib treatment